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Many patients with schizophrenia receive long-term treatment with antipsychotic medication. Switching of
antipsychotic medication due to lack of efficacy, tolerability issues, and partial/non-adherence is common. Despite
this, consensus strategies for switching between antipsychotics are lacking. This manuscript provides practical
recommendations for switching antipsychotic medication to ensure optimal management of patients with
schizophrenia, with a particular focus on paliperidone extended release (ER). The authors drew on their clinical
experience supported by detailed discussion of literature describing antipsychotic switching techniques and
strategies and findings from paliperidone ER clinical trials. Antipsychotic switching strategies should be
individualized and take into consideration the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the
pre- and post-switch medication. The use of temporary concomitant medications may be appropriate in some
scenarios. Abrupt withdrawal of pre-switch medication may be appropriate in some instances but carries a greater
risk of rebound and withdrawal symptoms than other strategies. Cross-tapering is the method most widely used in
clinical practice. Paliperidone ER can be initiated without dose titration. The EU SmPC recommended dose of
paliperidone ER is 6 mg/day; but doses should be individualized within the approved range of 3–12 mg/day. Higher
doses may be required due to insufficient efficacy of the previous antipsychotic or in patients with acute symptoms.
Recently diagnosed patients, those with renal impairment, or patients who have previously experienced tolerability
issues with other antipsychotics may require lower doses. When switching from risperidone, higher doses of
paliperidone ER may be required compared with risperidone. When switching from antipsychotics that have
sedative and/or significant anticholinergic activity, the pre-switch antipsychotic should be tapered off gradually.
Antipsychotics with less sedating and little anticholinergic activity can be tapered off over a shorter period.
Temporary concomitant sedative medication may be beneficial when switching from antipsychotics with relatively
higher sedative propensities. Switching from another antipsychotic to paliperidone ER requires individualized
switching strategies and dosing, dependent on the characteristics of the patient and the PK and PD properties of
the pre-switch medication. Cross-tapering strategies should be considered as a means of reducing the risk of
rebound and withdrawal symptoms.
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Schizophrenia is a chronic debilitating illness that nega-
tively impacts upon virtually all aspects of patients' lives.
Following a first episode, only 10%–15% of patients with
schizophrenia are free from further episodes, with many
patients displaying exacerbations and experiencing clinical
deterioration [1]. With each relapse, remission of symp-
toms may be slower and the course of illness worsened
[2,3]. The chronic nature of the disease means that most
patients are likely to receive antipsychotic treatment for
the remainder of their lives.
Discontinuation and frequent switching of antipsychotic
medication are common in the treatment of patients with
schizophrenia. Reasons for discontinuing or switching
antipsychotic medications can include lack of efficacy
[4], tolerability issues [4], partial or non-adherence to
medication [2,4], relapse despite adherence to medication
[5], impaired functioning [6], or patient decision [7].
The Clinical Antipsychotic Trials of Intervention Effect-
iveness (CATIE) [7] involved 1,492 patients randomized
to receive either the oral first-generation antipsychotic
(FGA) perphenazine or one of a number of oral second-
generation antipsychotics (SGAs) (olanzapine, quetia-
pine, risperidone, or ziprasidone) for up to 18 months.
This study highlighted that 74% of patients discontin-
ued the antipsychotic medication they were assigned at
randomization before the end of the 18-month period.
The most common reasons for discontinuation were
lack of efficacy and intolerable side effects. When com-
pared with FGAs, SGAs are generally more effective
against negative and affective symptoms with a better
tolerability profile, particularly with regard to extrapyr-
amidal symptoms (EPS) [8-13]. However, SGAs reflect a
group of heterogeneous medications [14] with some
considerable differences in both efficacy [15] and toler-
ability [16], including weight gain, metabolic changes,
and prolactin-related side effects [17]. For example, a
recent randomized controlled study demonstrated com-
parable efficacy, but at the same time, significantly re-
duced metabolic side effects with paliperidone extended
release (ER) compared with olanzapine [18]. In addition, a
survey conducted in Europe, the Middle East, and Africa
suggested that 34% of psychiatrists would consider al-
tering their patient's pharmacotherapy if they believed
the patient to have impaired social functioning, while
27% of respondents indicated that switching antipsy-
chotics would be their preferred pharmacological strategy
in order to address deficits in social functioning in patients
with schizophrenia [19].
In Europe, consensus guidelines suggest that the initial
choice of antipsychotic medication or the decision to
switch to a new antipsychotic medication should be
made on the basis of individual patient preference, prior
treatment response, experience of side effects, adherencehistory, relevant medical history and risk factors, medica-
tion side-effect profile, and long-term treatment planning
[20-22]. An international consensus study [23] of anti-
psychotic dosing in psychiatric illness reported dosing
recommendations and consensus estimates of clinically
equivalent doses, including an equivalency ratio for pali-
peridone ER compared with chlorpromazine and with
olanzapine. This study also reported a number of patient-
related factors that may affect these dosing recommenda-
tions [23]. Nevertheless, consensus strategies for switching
between different antipsychotic treatments are lacking.
This manuscript aims to provide practical recommen-
dations for switching antipsychotics, with a particular
focus on paliperidone ER, to ensure the optimal manage-
ment of patients with schizophrenia.
Review
The authors drew on their clinical experience to develop
this review manuscript, which provides practical recom-
mendations for dosing and switching to paliperidone ER.
The clinical experience is reflected within this manuscript
and is supported by a detailed discussion of pertinent lit-
erature, as reviewed by the authors, including articles de-
scribing antipsychotic switching techniques and strategies,
and findings from paliperidone ER clinical trials.
Considerations when switching antipsychotic medication
Switching antipsychotic treatments can deliver potential
benefits. These may include improved efficacy, tolerability,
adherence, functioning, and quality of life, while reducing
hospitalization rates [4].
A number of factors should be considered when switch-
ing antipsychotic treatment. Indications and contraindica-
tions to switching should be considered on an individual
patient basis [5]. Other considerations include the poten-
tial risk of withdrawal symptoms [24], re-emergence of
psychotic symptoms [24], perceptions of patients and
their families regarding the new treatment [6], presence
of stressful life events [6], and the potential introduction
of new or unfamiliar adverse effects, some of which, e.g.
weight gain may have a long-term negative impact on
the patient's health [17,24]. It is important to carefully
consider both the method of switching and follow-up
plans, prior to an antipsychotic treatment switch [5].
Furthermore, it is essential to carefully review the patient's
treatment history [5] and provide patient education (and
educate the family/carer, if appropriate) regarding the
switching procedure, potential withdrawal symptoms, and
risk and signs of relapse [5,6]. Psychoeducation may also
be beneficial [6]. Consideration of the pharmacokinetic
(PK) and pharmacodynamic (PD) profiles of antipsychotic
medications are crucial for successful titration, dosing,
and switching. This includes consideration of differences in
receptor binding affinities, in particular for dopaminergic,
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carinic receptors (Table 1).
It is important to note that the greater the differences
in receptor binding affinities between pre- and post-switch
antipsychotic medications, the more care should be taken
when switching. This is due to the increased risk of side
effects or withdrawal symptoms or PD rebound phe-
nomena (Table 2). For example, switching from an anti-
psychotic with higher affinity for cholinergic receptors
(e.g., olanzapine or clozapine) or histaminergic receptors
(e.g., olanzapine, quetiapine, or clozapine) to one with lower
affinity for cholinergic or histaminergic receptors (e.g.,
risperidone, paliperidone, or aripiprazole) may cause transi-
ent rebound insomnia, anxiety, agitation, or restlessness
(due to a decreased propensity for anticholinergic and/
or antihistaminergic effects). A PK dopamine rebound
effect may also occur when switching from a shorter half-
life antipsychotic (e.g., immediate release quetiapine or
ziprasidone) to a longer half-life antipsychotic, such as
paliperidone ER or vice versa (Table 1).
Switching scenarios
Various methods are available for switching antipsychotic
treatments [5]. These include abrupt withdrawal of pre-
switch medication and initiation of post-switch medication,
gradual withdrawal of pre-switch medication and initiation
or titration of post-switch medication, and cross-tapering.
Abrupt withdrawal of pre-switch medication and initiation
of post-switch medication entails abrupt cessation of
the current medication, possibly with the inclusion of a
washout period, followed by immediate initiation of a
new medication. The option of gradual withdrawal of
pre-switch medication and initiation of post-switchTable 1 Approximate receptor binding profiles and half-lives
antipsychotics
Receptor Paliperidone [25,26] Risperidone Olanzapine
Receptor binding affinity expressed as equilibrium constant (Ki)b
D2 1.6 [25] 4 [27] 11 [27]
5-HT2A 1.1 [25] 0.5 [27] 4 [27]
α1 2.5c [25] 0.7 [27] 19 [27]
α2 d 3.9e [25] 3 [27] 230 [27]
H1 19 [25] 20 [27] 7 [27]
M1 >10,000 [25] >10,000 [27] 1.9 [27]
Pharmacokinetic profiles, half-life
t1/2, h 23
f [28] 3 [29] 20–70 [30]
Tmax, h 24 [28] 1–2 [29] 5–8 [32]
Bioavailability, % 28 [28] 70 [29] 60–80 [30]
aData refer to the quetiapine immediate release formulation; bdata represented as n
cthis value relates specifically to affinity for the α1A receptor;
dpaliperidone may hav
relates specifically to affinity for the α2A receptor;
fdata refer to paliperidone extend
2A receptor; α, alpha-adrenergic receptor; H, histaminergic receptor; M, muscarinic
is achieved.medication allows for gradual tapering of the current
medication, followed by the initiation of a new medication
via slowly increasing doses, with or without a washout
period. Finally, cross-tapering allows gradual tapering of
the current medication while immediately or gradually
starting a new medication [24]. These switching strategies
are highlighted in Figure 1 [24].
Remington et al. [41] conducted a meta-analysis to inves-
tigate the effect of immediate versus gradual antipsychotic
switching strategies on effectiveness (as measured by Clin-
ical Global Impression-Severity (CGI-S) and Positive and
Negative Syndrome Scale (PANSS) total, positive and
negative scores) and tolerability (as measured by the most
common adverse event reported in each study, in addition
to insomnia and somnolence). Differences in outcomes
were independent of pre- and post-switch strategy. How-
ever, recent trials have shown that strategies involving a
gradual reduction of pre-switch antipsychotic lead to
fewer patient dropouts [42,43].
Abrupt withdrawal of pre-switch medication and
initiation of post-switch medication, with or without a
washout period, is the switch method most often used
in randomized controlled clinical trials. In clinical trials,
rescue medications, often unspecified, are frequently used
in order to counter problems of abrupt switching, a prac-
tice that is less common in clinical practice [4]. Abrupt
withdrawal of pre-switch medication and initiation of
post-switch medication may be necessary in some cases,
in particular when severe or acute adverse events with the
current treatments (such as agranulocytosis, important
electrocardiographic abnormalities, or other severe into-
lerable side effects) are observed [5]. However, abrupt
withdrawal of the pre-switch medication has a greaterof selected first-generation and second-generation
Quetiapinea Ziprasidone Clozapine Aripiprazole Haloperidol
160 [27] 5 [27] 126 [27] 0.45 [27] 0.7 [27]
295 [27] 0.4 [27] 16 [27] 3.4 [27] 45 [27]
7 [27] 10 [27] 7 [27] 57 [27] 6 [27]
87 [27] – [27] 8 [27] – [27] 360 [27]
11 [27] 47 [27] 6 [27] 61 [27] 440 [27]
120 [27] >1,000 [27] 1.9 [27] >10,000 [27] >1,500 [27]
5–8 [30] 4–10 [30] 6–33 [30] 48–68 [30] 20 [31]
1–2 [33,34] 4–6 [35] 0.4–4.2 [36] 3–5 [37] 4.9 [38]
9 [39] 60 [30] 12–81 [30] 87 [30,37] 44–74 [31]
anomolar concentration required to block 50% of receptors in vitro (Ki [nM]);
e higher receptor affinity for the α2A receptor than risperidone [26];
ethis value
ed release formulation. D2, dopamine type 2 receptor; 5-HT2A, serotonin type
receptor; t1/2, half-life; Tmax, time at which maximum plasma drug concentration
Table 2 Effects of blockade of receptors and side effects that can result from withdrawal/rebound during switching
Receptor Effects of blockade Potential rebound/withdrawal effect
D2 Antipsychotic, antimanic, antiaggression, EPS/akathisia, tardive
dyskinesia, increased prolactin
Psychosis, mania, agitation, akathisia, withdrawal
dyskinesia
α1 Postural hypotension, dizziness, syncope Tachycardia, hypertension
α2 Antidepressant, increased alertness, increased blood pressure Hypotension
H1 Anxiolytic, sedation, sleep induction, weight gain, anti-EPS/akathisia Anxiety, agitation, insomnia, restlessness, EPS/akathisia
M1 (central) Negative impact on memory and cognition, dry mouth, anti-EPS/
akathisia
Agitation, confusion, psychosis, anxiety, insomnia,
sialorrhoea, EPS/akathisia
M2–4 (peripheral) Blurred vision, constipation, urinary retention, tachycardia,
hypertension
Diarrhoea, sweating, nausea, vomiting, bradycardia,
hypotension, syncope
5-HT1A (partial agonism) Anxiolytic, antidepressant, anti-EPS/akathisia Anxiety, EPS/akathisia
5-HT2A Anti-EPS/akathisia, antipsychotic EPS/akathisia, psychosis
5-HT2C Increased appetite/weight Decreased appetite
D2, dopamine type 2 receptor; EPS, extrapyramidal symptoms; α, alpha-adrenergic receptor; H, histaminergic receptor; M, muscarinic receptor; 5-HT1A, serotonin
type 1A receptor; 5-HT2A, serotonin type 2A receptor; 5-HT2C, serotonin type 2C receptor. Adapted from [40].
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[5] and carries a greater risk for relapse than more gradual
withdrawal [44]. Withdrawal symptoms and rebound
phenomena can be minimized by using gradual or cross-
tapering approaches when the pre- and post-switch recep-
tor affinities and/or half-lives differ considerably. However,
gradual tapering may result in suboptimal dosing for a
number of weeks [5]. Alternatively, in cases where the
completion of the switch needs to be hastened, benzo-






















Figure 1 Switching techniques for second-generation antipsychotic m
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Eltanaihi-Furtmuller N, Hummer M, Fleischhacker WW, Figure 1 [24].mirtazapine, or non-benzodiazepine anxiolytics/sedatives
(Table 3) can be used in a time-limited, prophylactic
manner. These strategies can also minimize the risk of
rebound phenomena.
Cross-tapering is generally the most widely used method
in clinical practice but should be used with caution
when the pre-switch antipsychotic has a shorter half-life
(e.g., immediate release quetiapine or ziprasidone) and/
or relatively greater antagonistic effects at muscarinic
(e.g., quetiapine, ziprasidone, or clozapine), histaminergicisadvantage Recommended for
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Table 3 Managing undesirable/rebound effects at




Corrective approach or (transient) concomitant
medications
Akathisia Lower dose, slow down switch
Add benzodiazepine, antihistamine, beta-blocker,
mirtazapine, gabapentin, low dose of low potency FGA
Mania,
psychosis
Slow/reverse down titration of prior antipsychotic, increase
new antipsychotic; add benzodiazepine, valproate
Agitation Slow switch, increase dose of new antipsychotic; add
benzodiazepines or low potency FGA, valproate
Anxiety Use lower starting dose, slow switch, restrict excessive
caffeine use, benzodiazepine, antihistamine, antidepressant,
gabapentin
Insomnia Slow switch, restrict excessive caffeine use, add low dose
of sedating SGA, benzodiazepine, non-benzodiazepine
hypnotic, antihistamine, trazodone
FGA, first-generation antipsychotic; SGA, second-generation antipsychotic.
Adapted from [40].
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than the post-switch antipsychotic. These considerations
impact both the tapering period of the pre-switch medica-
tion (for instance, requiring prolongation) and the dosing
of the new antipsychotic medication.
Switching strategies should take account of the specific
medications involved; for example, switching from a sedat-
ing to a non-sedating antipsychotic requires different
considerations than switching between two sedating antipsy-
chotics. Temporary use of concomitant medications may
be appropriate in some situations, for example when switch-
ing from an antipsychotic with anticholinergic or sedative
properties to one without [5]. Specifically, a patient who is
agitated and cannot sleep may require short-term supple-
mentation with a benzodiazepine or another sedating medi-
cation when treatment with a non-sedating agent is
initiated. This approach gives the ability to control insomnia,
enabling discontinuation of the sedating medication when it
is no longer needed [45]. The potential for drug–drug in-
teractions, such as hepatic CYP-450 induction or inhib-
ition, which occur not only when introducing but also
when reducing the dose or tapering of enzyme-inducing
or -inhibiting drugs, should also be considered [40].
The most appropriate switching strategy may differ for
each patient and even according to the individual clinical
situation within the same patient at different stages of
the disease and should therefore be considered on an
individual basis [21].
Paliperidone ER: clinical efficacy
Paliperidone ER is indicated for the treatment of schizo-
phrenia in adults as well as for the treatment of psychotic
or manic symptoms of schizoaffective disorder [28,46]. The
OROSW technology utilized in paliperidone ER ensuresstable plasma drug concentrations over a 24-h period
and means that paliperidone ER may be initiated at thera-
peutically effective doses without the need for initial titra-
tion [47].
The efficacy and tolerability of the approved dose range
of paliperidone ER (3–12 mg/day) was established in three
multi-centre, placebo-controlled, double-blind, fixed-dose,
6-week pivotal trials in patients with acute symptoms of
schizophrenia [48-51]. All tested doses of paliperidone ER
separated from placebo from day 4 on the primary efficacy
endpoint (a decrease in PANSS total scores) [28,48-50]. In
all three studies, paliperidone ER was also superior to pla-
cebo on secondary endpoints; improvement in patient
functioning based on the Personal and Social Performance
(PSP) scale and improvement in symptoms as assessed
using the CGI-S scale. In a further 6-week study, paliperi-
done ER (6–12 mg/day) was associated with significantly
greater improvements in symptoms from baseline at
2 weeks (p < 0.01) and at 6 weeks (p < 0.05) post-initiation,
in patients with acutely exacerbated schizophrenia requir-
ing hospitalization, compared with quetiapine (600–
800 mg/day) [52]. In open-label extension studies of the
three key trials described above, long-term administration
of paliperidone ER maintained improvements in symp-
toms and functioning and was generally well-tolerated for
up to 52 weeks [53]. In a long-term trial designed to assess
the maintenance of its effect, paliperidone ER was signifi-
cantly more effective than placebo in maintaining symp-
tom control and in extending time to relapse of
schizophrenia [54]. Taken together, these studies demon-
strate that paliperidone ER is an effective choice for the
treatment of acute symptoms and prevention of relapse in
patients with schizophrenia [8,48-50,53,54].
The studies described above used fixed dosing and
washout periods in selected patient populations. The
majority of fixed-dose randomized controlled studies
are required for licensing purposes and provide some
initial information on dosing recommendations. Two
additional pragmatic studies using flexible doses of
paliperidone ER in routine clinical practice were there-
fore conducted to complement the pivotal studies and
provide further information regarding appropriate dosing
in acute and non-acute patients, respectively. These stud-
ies demonstrated that flexible dosing of paliperidone ER
was associated with significant improvements in symp-
tomatology and functioning in patients with an acute ex-
acerbation of schizophrenia [55] and in non-acute but
symptomatic patients who had previously been unsuc-
cessfully treated with oral antipsychotics [56].
Paliperidone ER in schizoaffective disorder
In the EU, paliperidone ER is also indicated for the treat-
ment of psychotic or manic symptoms of schizoaffective
disorder in adults [28]. The efficacy and tolerability of
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toms of schizoaffective disorder have been demonstrated
in two double-blind, randomized, placebo-controlled stud-
ies [57,58]. Dosing recommendations for paliperidone ER
in patients with schizoaffective disorder are 6 mg per day
(some patients may benefit from higher doses, within a
recommended range of 6–12 mg per day [28]) and overall,
the same switching recommendations apply.Table 4 Dosing considerations when switching non-acute
patients with schizophrenia from other oral atypical
antipsychotics to paliperidone ER
Prior oral antipsychotic
medication





Olanzapine 10a 6aPaliperidone ER: clinical efficacy after switching from
other oral antipsychotics
The clinical benefits of switching to paliperidone ER
have been demonstrated in both acute and maintenance
treatment. To study these benefits in the acute setting, a
6-week flexible-dose study was performed in which 294
patients with an acute exacerbation of schizophrenia
were switched to paliperidone ER (3–12 mg/day; mean
initial dose, 5.8 ± 1.7 mg/day; mean mode dose, 7.7 ±
2.6 mg/day; the proportion of patients receiving 9 or
12 mg/day at study end, 33% and 21%, respectively)
[55]. Results of this study demonstrated clinically relevant
and statistically significant improvements from baseline
in PANSS total score, patient functioning (as measured
by PSP score), sleep quality, and daytime drowsiness (all
p < 0.0001). To study the clinical benefits of switching
to paliperidone ER, patients with non-acute schizophre-
nia, who had previously received risperidone but were
sufficiently symptomatic for enrolment, were switched
to paliperidone ER (3–12 mg/day). Results indicated
that paliperidone ER significantly improved psychotic
symptoms, disease severity, and patient functioning (as
measured by PANSS, CGI-S, and PSP scores, respect-
ively) compared with those on placebo (p < 0.05) [59].
In patients who were previously unsuccessfully treated
with other oral antipsychotics and then switched to flex-
ibly dosed paliperidone ER (3–12 mg/day), PANSS general
psychopathological symptoms, as well as PANSS positive,
negative, and total scores, significantly decreased from
baseline to endpoint [56]. The main reasons for discon-
tinuing the previous oral antipsychotic medication in these
studies were lack of efficacy (56.6%), lack of tolerability
(27.0%), and lack of adherence (9.1%) [56].14.2b [56] 7.2c [63]
Risperidone 5a 6a
4.3b [56] 7.1 [64]
Quetiapine 400a 6a
485.3b [56] 6.8c [65]
Aripiprazole 15a 6a
19.4b [56] 6.8 [66]
aWHO DDD (mg) [67]; blast used mean daily dose; cdoses of up to 9 mg/day
may be required depending on the individual patient circumstances [68].
WHO, World Health Organization; DDD, defined daily dose; ER, extended
release.Practical considerations when treating patients with
paliperidone ER
Paliperidone ER receptor profile
Paliperidone ER has a greater affinity for serotonin type
2A (5-HT2A) receptor relative to dopamine type 2 (D2)
receptor and a very low affinity for muscarinic receptors
[60,61]. A dose of 6–9 mg of paliperidone ER provides a
mean D2 receptor occupancy of 70%–80%, reflecting the
accepted receptor occupancy range required for optimal
antipsychotic activity without increased risk of EPS [62].Paliperidone ER recommended dose
Three pivotal studies [48-50] of paliperidone ER exam-
ined the licensed dose range of 3–12 mg/daya in pa-
tients with acute symptoms of schizophrenia. In these
fixed-dose studies, the incidence of EPS was higher at
doses ≥9 mg/day. Evidence from these trials suggested that
a dose of 6 mg/day provides a good efficacy/tolerability
ratio for a considerable number of patients [28,51]. How-
ever, clinical studies and the authors' clinical experience
indicate that doses >6 mg/day may be useful for patients
who are, for example acutely ill or in a post-acute phase,
suffering from relevant breakthrough symptoms or who
have needed higher doses of previous antipsychotic medi-
cations in the past. This is supported by a recent clinical
trial in which patients suffering from an acute exacerba-
tion of schizophrenia received flexibly dosed paliperidone
ER (3–12 mg/day) for 6 weeks [54]. In addition, a number
of flexible-dose studies of paliperidone ER have high-
lighted that, based on patients' needs, dosing is often indi-
vidualized during the course of treatment [54-56]. Indeed,
the flexible dosing option led to upward titration more
often than downward titration [54-56,59-62]. This is also
likely to reflect clinical practice.
Paliperidone ER: switching considerations
Post-switch dosage of paliperidone ER
Dosing of paliperidone ER following a treatment switch
is likely to depend on a number of factors such as the
reasons for switching antipsychotic medication, the type
and dose of previous antipsychotic medication, and patient
characteristics. The mean doses of paliperidone ER after
switching from other antipsychotics are highlighted in
Table 4.
Subgroup analyses of a large, pragmatic trial including
more than 1,800 patients have shown that switching to
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antipsychotic medication is associated with a tendency for
higher paliperidone ER dosing compared with switching
for other reasons, such as lack of tolerability or adherence
issues [56].
In acutely ill patients, a higher baseline CGI-S score
has also been demonstrated to be a significant predictor
for patients requiring a higher than 6 mg paliperidone
ER dose/day [68]. In addition, higher body mass index
and a higher number of hospitalizations in the preceding
12 months were predictive of a mode dose of 9 mg/day
in severely acutely exacerbated patients [68]. However,
age, baseline PANSS total score, and baseline PSP score
do not appear to be predictive of higher dosing [68].
Acutely ill patients may require higher dosages of
paliperidone ER, [68] and use of paliperidone ER in the
highly acute hospital setting may be associated with doses
of ≥9 mg/day [55]. Furthermore, patients at imminent risk
of relapse may also require higher doses [54].
Some patients may benefit from lower doses of
paliperidone ER, for example patients with renal im-
pairment [28], patients who have previously experienced
side effects, or patients who show higher susceptibility to
adverse effects of antipsychotics. Clinical experience of
using paliperidone ER suggests that recently diagnosed pa-
tients with schizophrenia may require lower doses than
those with more chronic illness [69]. Paliperidone ER is
generally well-tolerated; however, akathisia and parkinson-
ism can occur in some patients, especially if doses in the
upper range are used (≥9 mg/day) [51], although rates
were lower when flexible doses of paliperidone ER were
allowed and treatment could be individualized to patients'
needs [56].
Paliperidone ER can be initiated at an effective dose
without the need for titration [28]. However, depending
on the clinical situation, post-switch titration may be
useful in some patients, for example, those sensitive to
or already experiencing side effects. In this case, cross-
tapering of paliperidone ER and the previous antipsychotic
may be useful.
Switching to paliperidone ER from oral risperidone
In the case of switching from oral risperidone to
paliperidone ER, doses that produce similar exposures of
active moiety at steady state cannot necessarily be con-
sidered to be ‘therapeutically equivalent’ in the clinic
[70]. A statistical analysis comparing data from several
clinical trials (in the absence of a specific, direct head-to-
head trial), demonstrated that higher doses of paliperidone
ER are required compared to those of risperidone. This
analysis suggests that 6–12 mg/day paliperidone ER pro-
duces similar efficacy to 4–6 mg/day of oral risperidone
[71]. These differences in required dose may be related to
the extended release profile of paliperidone followingadministration of paliperidone ER (peak plasma concen-
trations occur at 24 h) [28], considerably lower bioavail-
ability (28% for paliperidone ER [28] versus ≥70% for oral
risperidone) [29], potentially slower brain penetration due
to its lower lipophilic properties [72] of paliperidone ER
compared with oral risperidone. The receptor-binding
profiles of risperidone and paliperidone are broadly
similar, with one suggested difference being paliperido-
ne's higher receptor affinity for the alpha 2A adrenergic
(α2A) receptor [25]. Rapid withdrawal is therefore a
commonly employed strategy when switching patients
from oral risperidone to paliperidone ER. However, as
data suggest that paliperidone ER is less sedating than ris-
peridone [26], patients may benefit from gradual with-
drawal or, if clinically indicated, temporary concomitant
treatment with a sedative medication.Switching to paliperidone ER from aripiprazole
Aripiprazole is both a D2 antagonist and a partial D2 and
5-HT1A agonist and 5-HT2A antagonist, with low poten-
tial for sedation [45]. It demonstrates the highest affinity
for D2 receptors among SGAs [25,27]. Both aripiprazole
and its active metabolite dehydroaripiprazole have a long
half-life, with an elimination half-life of 47 to 68 h after
a single dosing of aripiprazole in healthy volunteers [73],
therefore relatively rapid discontinuation of aripiprazole
is possible during a treatment switch.Switching to paliperidone ER from oral olanzapine or
quetiapine
Olanzapine and quetiapine are antipsychotics known to
have sedative and anticholinergic properties. Both are po-
tent D2/5-HT2 receptor antagonists and are also histamine
H1 and muscarinic M1 receptor antagonists. H1 antagon-
ism is the likely pathway for the sedating effects of these
antipsychotics [74], whilst M1 antagonism is believed to be
responsible for their anticholinergic activity. According to
pharmacological principles applied in daily clinical prac-
tice and based on the PD properties of paliperidone ER
(which is generally considered to have a low propensity
for sedation and has a low potency at the M1 receptor), ta-
pering off of these medications should be conducted over
approximately 2–4 weeks (and occasionally longer), de-
pending on the dose of olanzapine or quetiapine used and
the sensitivity of the patient. As olanzapine and quetiapine
have a greater propensity to cause sedation than paliperi-
done ER [18,52], clinical experience suggests that in indi-
vidual patients, temporary concomitant use of sedative/
hypnotic medications may be useful in order to avoid
insomnia and anxiety when switching from oral olanza-
pine or quetiapine. The same principles would apply to
switching from clozapine, although in clinical practice
this is not expected to occur frequently.
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It is important that questions related to the use of con-
comitant medication be considered when switching anti-
psychotics. Paliperidone ER is not expected to cause
clinically important hepatic PK interactions with drugs
that are metabolized by cytochrome P450 isozymes [75].
Therefore, it is not expected to induce or inhibit clear-
ance of drugs that are metabolized by these metabolic
pathways in a clinically relevant manner.
Paliperidone ER has a low potential for sedation
[18,26,51,55,59]; therefore, the use of benzodiazepines
or other sedating drugs may be helpful if switching from
a sedating antipsychotic to paliperidone ER. Patients
who are acutely ill, agitated, and/or suffer from insom-
nia may need short-term supplementation with a benzo-
diazepine, non-benzodiazepine hypnotic, sedating SGA
(e.g., quetiapine) or a low-potency FGA (e.g., levome-
promazine). In a 6-week study [49], analyzing the safety
and efficacy of once-daily paliperidone ER, 63–66% of
patients receiving paliperidone ER received benzodiaze-
pines as compared with 72% in the placebo group. The
most commonly used benzodiazepine was lorazepam,
with an average daily dose of 2.7 ± 1.2 to 3.2 ± 1.5 mg
and a mean duration of 10.3–12.2 days across all treat-
ment groups [49]. In a study of patients with an acute
exacerbation of schizophrenia switching to paliperidone
ER, a higher baseline CGI-S score was associated with a
greater likelihood of concomitant benzodiazepine use
[68]. Mean doses of benzodiazepine used were 14.4 ±
8.5 mg/day diazepam equivalents [68]. Transient con-
comitant use of benzodiazepine comedication for a limited
period of approximately 10 days may be useful in acutely
ill patients [55] and non-acute patients suffering from
breakthrough symptoms or insomnia. Similarly, in the
case of EPS, temporary concomitant anticholinergic
medication can be used [55].
The use of concomitant medications during an anti-
psychotic switch should, in most cases, be temporary.
It is therefore important to conduct regular clinical as-
sessments following the switch in order to determine
whether the concomitant medication is still required.
Conclusions
Taken together, a number of studies have demonstrated
that paliperidone ER is a useful option in the treatment
of acute symptoms and in maintenance treatment including
the prevention of relapse in patients with schizophrenia
[48-53,76,77], including in those patients unsuccessfully
treated with other oral antipsychotics [18,55,56,59], as well
as in patients with schizoaffective disorder [57,58]. It is
therefore important to consider dosing and switching
strategies to ensure the optimal management of patients
with schizophrenia who may benefit from a switch from
another oral antipsychotic to paliperidone ER treatment.Future studies will provide additional information on
switching strategies for the long-acting injectable formula-
tion of paliperidone, paliperidone palmitate.
This manuscript outlines the recommendations for
dosing paliperidone ER and for switching to paliperidone
ER in patients with schizophrenia in different clinical situ-
ations. Data from recent flexible dose studies in real-world
clinical settings have demonstrated that patients will have
differing dose requirements based on individual needs
[55,56,59], with an appropriate switching strategy for pa-
tients who have previously been unsuccessfully treated
with other oral antipsychotics. Reasons for switching can
include lack of efficacy, poor tolerability, partial or non-
adherence to medication, or patient wish. The pharmaco-
logical profile of paliperidone ER, the type and dose of the
previous antipsychotic(s), the clinical situation (e.g., acute/
non-acute) and the individual patient profile (e.g., severity
of symptoms, sensitivity to side effects, previous treatment
responses, or need for higher dosages) should be taken
into account when switching patients with schizophrenia
or schizoaffective disorder.
Endnotes
aA higher dose of 15 mg/day was also included in one
of the clinical trials [48]; however, this dose is outside of
the approved dose range.
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